Health
New Covid-19 vaccine demonstrates ‘89% efficacy’ with UK having 60m orders – expressandstar.com
A trial was carried out in conjunction with the UK Government’s Vaccine Taskforce.
An experimental Covid-19 vaccine appears to offer strong protection in late-stage UK and South Africa studies, said manufacturer Novavax.
The UK has secured access to 60 million doses of the vaccine, called NVX-CoV2373.
The protein-based vaccine candidate was shown to be 89.3% effective at preventing coronavirus in participants in its Phase 3 clinical trial in the UK, which enrolled more than 15,000 people between 18-84, of which 27% were older than 65, Novavax said.
NVX-CoV2373 is the first vaccine…
-
Noosa News19 hours agoYoung voices shape Sunshine Coast’s future
-
Business19 hours ago2 Low Cost Active ASX ETFs to consider
-
Noosa News18 hours agoQueensland government to review greenhouse gas emission reduction targets
-
Noosa News16 hours agoCopperString transmission line projected to cost almost $14b amid massive blowout